Fresenius Kabi USA Issues Voluntary Nationwide Recall of Benztropine Mesylate Injection, USP 2 mg/2 mL (1 mg/mL), in 2 mL Single Dose Vials

You are subscribed to Recalls, Market Withdrawals and Safety Alerts for U.S. Food & Drug Administration (FDA).

This information has recently been updated and is now available.

 

Fresenius Kabi USA Issues Voluntary Nationwide Recall of Benztropine Mesylate Injection, USP 2 mg/2 mL (1 mg/mL), in 2 mL Single Dose Vials

07/01/2013 06:12 PM EDT

LAKE ZURICH, Ill. - Fresenius Kabi USA is voluntarily recalling four lots of Benztropine Mesylate Injection, USP, 2 mg/2mL (1mg/mL) in 2 mL single dose vials due to the potential presence of glass particles (glass delamination) in the vials. This recall is being conducted to the user level.

. For detailed information pertaining to this Recalls, Market Withdrawals and Safety Alerts message, please click the link at the beginning of this bulletin.

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? support@govdelivery.com
• Other inquiries? webmail@oc.fda.gov

---

This email was sent to filter@clubhouseb.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420